Stock NXL NEXALIN TECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nexalin Technology, Inc.

Equities

NXL

US65345B2016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-15 pm EDT 		5-day change 1st Jan Change
1.36 USD -0.73% Intraday chart for Nexalin Technology, Inc. +12.40% +235.97%
May. 10 Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Nexalin Technology Regains Compliance With Nasdaq Listing Requirement MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
GL
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement
MT
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
GL
Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device
PU
Nexalin Technology Files $5.6 Million Shelf Registration
MT
Nexalin Technology CEO Provides Letter to Shareholders
AQ
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
GL
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing
CI
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
GL
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
AQ
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
GL
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board
CI
Top Midday Gainers
MT
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
GL
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
CI
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
GL
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman
CI
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NXL Stock
  4. News Nexalin Technology, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW